Immunomodulatory and pharmacologic properties of imiquimod.

Imiquimod, an imidazoquinoline amine, is an immune response modifier recently approved for the topical treatment of external genital and perianal warts. Although the majority of immunomodulatory agents available or in development inhibit pathways involved in immune activation, imiquimod is unique in that it activates immune function. The exact mechanism of imiquimod's antiviral activity is unknown; however, its effects are likely to be related to its immunomodulating properties. Although in vitro studies have shown that imiquimod has no direct antiviral effects, the drug does exhibit antiviral and antitumor effects in vivo through induction of cytokines and enhancement of cell-mediated cytolytic antiviral activity. Imiquimod stimulates the innate immune response through induction of cytokines, and the cellular arm of acquired immunity through induction of interferon-alpha (IFN-alpha), IFN-gamma, and interleukin-12. Results from animal studies have indicated a possible use for imiquimod in the prevention and treatment of herpes simplex virus infection. In addition, recent studies demonstrated that imiquimod activates Langerhans' cells and enhances allergic contact hypersensitivity.

[1]  C. Baglioni,et al.  Loss of (2'-5')oligoadenylate synthetase activity by production of antisense RNA results in lack of protection by interferon from viral infections. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M J Reiter,et al.  Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. , 1992, Cancer research.

[3]  P. Amerio,et al.  Imiquimod, a novel topical immune response modifier induces migration of langerhans cells , 1998 .

[4]  C. Ahonen,et al.  Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. , 1999, Cellular immunology.

[5]  R. Miller,et al.  Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways , 1995, Molecular and cellular biology.

[6]  R. Miller,et al.  Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. , 1999, Cellular immunology.

[7]  D. Bernstein,et al.  Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. , 1993, The Journal of infectious diseases.

[8]  S. Kondo,et al.  Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. , 1994, Lymphokine and cytokine research.

[9]  R. Miller,et al.  Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. , 1999, Antiviral research.

[10]  D. Bernstein,et al.  Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs. , 1991, Antiviral research.

[11]  R. Miller,et al.  Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[12]  R. Miller,et al.  The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. , 2000, Clinical immunology.

[13]  C. Weeks,et al.  Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. , 1994, Journal of interferon research.

[14]  M. Biffi,et al.  Selective Expression of an Interleukin-12 Receptor Component by Human T Helper 1 Cells , 1997, Journal of Experimental Medicine.

[15]  Richard L. Miller,et al.  Cytokine induction in mice by the immunomodulator imiquimod , 1994, Journal of leukocyte biology.

[16]  D. Bernstein,et al.  Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs , 1994, Antimicrobial Agents and Chemotherapy.

[17]  D. Bernstein,et al.  Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs. , 1995, Vaccine.

[18]  D. Bernstein,et al.  Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections , 1989, Antimicrobial Agents and Chemotherapy.

[19]  R. Miller,et al.  Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. , 2000, The Journal of investigative dermatology.

[20]  H. B. Slade,et al.  Imiquimod 5% cream (Aldara). , 1998, Expert opinion on investigational drugs.

[21]  M. Chen,et al.  Efficacy of S26308 against guinea pig cytomegalovirus infection , 1988, Antimicrobial Agents and Chemotherapy.

[22]  R. Miller,et al.  Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. , 1998, The Journal of investigative dermatology.

[23]  D. Bernstein,et al.  Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. , 1988, Antiviral research.

[24]  H. Maibach,et al.  Cutaneous infection and therapy. , 1997 .

[25]  M. Stanley,et al.  A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. , 1998, The Journal of infectious diseases.

[26]  T. Testerman,et al.  Cytokine induction by the immunomodulators imiquimod and S‐27609 , 1995, Journal of leukocyte biology.